GlaxoSmithKline (GSK) has signed an agreement to acquire the 36.5% stake held by Novartis in their Consumer Healthcare joint venture (JV) for $13bn.

Launched in 2015, the JV included a three-part inter-conditional transaction between the companies. Under the deal, Novartis has the right to require GSK to buy its stake.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The divestiture is expected to help Novartis to develop and advance its core businesses, and will provide GSK with 100% ownership to the JV.

Novartis CEO Vas Narasimhan said: “While our consumer healthcare JV with GSK is progressing well, the time is right for Novartis to divest a non-core asset at an attractive price.

“This will strengthen our ability to allocate capital to grow our core businesses, drive shareholder returns, and execute value creating bolt-on acquisitions as we continue to build the leading medicines company, powered by digital and data.”

“For the group, the transaction is expected to benefit adjusted earnings and cash flows, helping us accelerate efforts to improve performance.”

GSK  intends to improve its science-based innovation and operational efficiencies to deliver sales growth, improve margins and generate attractive returns.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company plans to launch a strategic review of its consumer healthcare nutrition products to fund this transaction.

GSK CEO Emma Walmsley said: “The proposed transaction addresses one of our key capital allocation priorities and will allow GSK shareholders to capture the full value of one of the world’s leading Consumer Healthcare businesses.

“For the group, the transaction is expected to benefit adjusted earnings and cash flows, helping us accelerate efforts to improve performance.”

GSK Consumer Healthcare reported sales of £7.8bn last year, with a 4% growth since 2015 on a three-year compound annual growth rate basis.

The acquisition is subject to approval by GSK shareholders.